Multiple and recurrent systemic thrombotic events associated with congenital anomaly of inferior vena cava.

Abstract:

:We describe a case of a 67-year-old woman with a history of cerebral infarction and pulmonary embolism that presented with chest pain. Subsequent evaluation resulted in a diagnosis of acute myocardial infarction and occult DVT, and imaging revealed a rare congenital absence of the infra-renal portion of the inferior vena cava, with lower extremity venous drainage diverted via an ascending lumbar vein. Associations between congenital absence of the inferior vena cava and thrombosis are discussed.

journal_name

J Thromb Thrombolysis

authors

Takehara N,Hasebe N,Enomoto S,Takeuchi T,Takahashi F,Ota T,Kawamura Y,Kikuchi K

doi

10.1007/s11239-005-1380-z

subject

Has Abstract

pub_date

2005-04-01 00:00:00

pages

101-3

issue

2

eissn

0929-5305

issn

1573-742X

journal_volume

19

pub_type

杂志文章
  • The thrombolytic effect of aspirin in animal model.

    abstract:BACKGROUND:The aspirin induced platelet aggregation has been reported to be mediated through the inhibition of platelet prostaglandin synthesis. This compound has also been recently reported to stimulate nitric oxide synthesis in platelets. Since nitric oxide has been reported to produce fibrinogen/fibrinolytic effect,...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0023-y

    authors: Karmohapatra SK,Kahn NN,Sinha AK

    更新日期:2007-10-01 00:00:00

  • Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism: comment.

    abstract::Kuperman et al. found that patients with anemia had a higher risk of major bleeding (RR 2.84; 95% CI 2.52-3.39) in RIETE database. Anemia appeared to be an independent predictive factor for major bleeding [hazard ratio (HR) 1.95; 95% CI 1.72-2.20] in this registry. Unfortunately, selection bias due to enrolled patient...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 信件,多中心研究

    doi:10.1007/s11239-018-1668-4

    authors: Gaboreau Y,Zenatti N,Vermorel C,Imbert P,Bosson JL,Pernod G

    更新日期:2018-07-01 00:00:00

  • Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.

    abstract::Arterial thrombosis is the leading causes of morbidity and mortality worldwide, whereas venous thrombosis is the most common preventable cause of hospital death. In either case, venous and arterial thrombosis should be considered autonomous entities, with only minor overlaps in terms of risk factors, predisposing cond...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-012-0748-0

    authors: Lippi G,Favaloro EJ,Franchini M

    更新日期:2012-10-01 00:00:00

  • Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.

    abstract:BACKGROUND:Venous thromboembolism (VTE) is a significant cause of mortality and morbidity in medical patients. Although thromboprophylaxis with enoxaparin reduces the risk of VTE in these patients, the optimal duration of therapy is not currently known. The EXCLAIM (EXtended CLinical prophylaxis in Acutely Ill Medical ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-006-7732-5

    authors: Hull RD,Schellong SM,Tapson VF,Monreal M,Samama MM,Turpie AG,Wildgoose P,Yusen RD

    更新日期:2006-08-01 00:00:00

  • Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications.

    abstract::The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis. There is ample evidence from both laboratory and clinical studies to suggest that in addition to...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-018-1641-2

    authors: Gorog DA

    更新日期:2018-05-01 00:00:00

  • Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more.

    abstract::The best strategy in atrial fibrillation (AF) after > 12 months after an acute coronary syndrome or in patients with chronic coronary syndrome without an indication for interventional revascularization remains unclear. European guidelines generally recommend therapy with oral anticoagulation (OAC) alone, whereas North...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,meta分析

    doi:10.1007/s11239-019-02007-4

    authors: Wernly B,Bhatt DL,Polzin A,Jung C

    更新日期:2020-02-01 00:00:00

  • EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy.

    abstract::Erythropoietin (EPO) was hypothesized to mitigate reperfusion injury, in part via mobilization of endothelial progenitor cells (EPCs). The REVEAL trial found no reduction in infarct size with a single dose of EPO (60,000 U) in patients with ST-segment elevation myocardial infarction. In a substudy, we aimed to determi...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-013-0944-6

    authors: Povsic TJ,Najjar SS,Prather K,Zhou J,Adams SD,Zavodni KL,Kelly F,Melton LG,Hasselblad V,Heitner JF,Raman SV,Barsness GW,Patel MR,Kim RJ,Lakatta EG,Harrington RA,Rao SV

    更新日期:2013-11-01 00:00:00

  • Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies.

    abstract::There is a significantly increased risk of pregnancy complications in women with anti-phospholipid syndrome (APS). The risk is further heightened in those with previous arterial or venous thromboembolism and so-called 'triple positivity' for anti-phospholipid antibodies (i.e., when lupus anticoagulant, and anti-cardio...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-014-1080-7

    authors: Rose HL,Ho WK

    更新日期:2014-11-01 00:00:00

  • Possible mechanisms of aspirin resistance.

    abstract::Data regarding possible mechanisms of aspirin (ASA) resistance in patients with recurrent myocardial infarction (MI) or vascular ischemia are limited. Five major possible mechanisms of ASA resistance are documented in the primary literature and are discussed in this paper. These mechanisms include: (1) inadequate bloc...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1023/a:1015324310374

    authors: Cambria-Kiely JA,Gandhi PJ

    更新日期:2002-02-01 00:00:00

  • Effect of Poloxamer 188 on Collateral Blood Flow, Myocardial Infarct Size, and Left Ventricular Function in a Canine Model of Prolonged (3-Hour) Coronary Occlusion and Reperfusion.

    abstract::Poloxamer 188 is a surfactant with hemorheological, antithrombotic, and neutrophil-inhibitory properties. This agent has been demonstrated to reduce infarct size and to improve left ventricular function in animal models of myocardial infarction and reperfusion, and recently in a randomized trial of patients receiving ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/A:1008848026759

    authors: Kelly RF,Hursey TL,Patel RB,Parrillo JE,Schaer GL

    更新日期:1998-07-01 00:00:00

  • Thrombolysis in Acute Myocardial Infarction Complicated by Cardiogenic Shock.

    abstract::The adverse impact of the development of cardiogenic shock in the setting of acute myocardial infarction was first described by Killip and Kimball in 1967. While the in-hospital mortality rate in patients with myocardial infarction and no evidence of heart failure was only 6%, the mortality rate in those patients who ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/BF01063156

    authors: Levine GN,Hochman JS

    更新日期:1995-01-01 00:00:00

  • Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia.

    abstract::Heparin-induced thrombocytopenia (HIT) is a prothrombotic condition and it is associated with increased in vivo thrombin generation that needs to be treated with non-heparin anticoagulants such as direct thrombin inhibitors (DTIs). DTIs require parenteral administration and are associated with a non negligible risk of...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-015-1208-4

    authors: Sartori M,Favaretto E,Cini M,Legnani C,Cosmi B

    更新日期:2015-10-01 00:00:00

  • The impact of a pulmonary embolism response team on the efficiency of patient care in the emergency department.

    abstract::The concept of a pulmonary embolism response team (PERT) is multidisciplinary, with the hope that it may positively impact patient care, hospital efficiency, and outcomes in the treatment of patients with intermediate and high risk pulmonary embolism (PE). Clinical characteristics of a baseline population of patients ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01875-0

    authors: Wright C,Elbadawi A,Chen YL,Patel D,Mazzillo J,Acquisto N,Groth C,Van Galen J,Delehanty J,Pietropaoli A,Trawick D,James White R,Cameron P,Gosev I,Barrus B,Kumar NG,Cameron SJ

    更新日期:2019-08-01 00:00:00

  • The pharmacology of novel oral anticoagulants.

    abstract::Anticoagulation for the prevention of stroke is an important aspect of the management of atrial fibrillation. Novel anticoagulants including oral factor Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran have emerged as important therapeutic treatment options for prevention of stroke i...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-013-0967-z

    authors: DeWald TA,Becker RC

    更新日期:2014-01-01 00:00:00

  • A pulmonary embolism response team (PERT) approach: initial experience from the Cleveland Clinic.

    abstract::Management of intermediate and high risk acute pulmonary embolism (PE) is challenging. The role of multidisciplinary teams for the care of these patients is emerging. Herein, we report our experience with a pulmonary embolism response team (PERT). We conducted a retrospective chart review on all patients admitted to t...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-018-1686-2

    authors: Mahar JH,Haddadin I,Sadana D,Gadre A,Evans N,Hornacek D,Mahlay NF,Gomes M,Joseph D,Serhal M,Tong MZ,Bauer SR,Militello M,Silver B,Shishehbor M,Bartholomew JR,Heresi GA

    更新日期:2018-08-01 00:00:00

  • Clinical validation of immunoassay HemosIL® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia.

    abstract::Heparin induced thrombocytopenia (HIT) is a life and limb-threatening complication of heparin exposure. The misdiagnosis of this disease can have major consequences on the patients. The objective of this study was to evaluate a diagnostic strategy that combines the 4Ts score with the result of HemosIL® AcuStar HIT-IgG...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02349-4

    authors: Marashi-Sabouni Z,Vayne C,Ibrahim-Kosta M,Guidon C,Loundou A,Guery EA,Morange PE,Camoin-Jau L

    更新日期:2021-01-01 00:00:00

  • Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin at Patient's Home.

    abstract::We have applied the low molecular weight heparin dalteparin as once-daily subcutaneous injections to the treatment of deep vein thrombosis (DVT) on an outpatient basis since 1994. Until today, 377 consecutive patients with DVT below the inguinal ligament have been treated at home with dalteparin. The patients administ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/A:1008866025015

    authors: Stockelberg D,Hansson E,Jonson T

    更新日期:1998-09-01 00:00:00

  • Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis.

    abstract::This study was intended to evaluate the cost-effectiveness of anticoagulation clinic care and self-testing for the management of patients on chronic warfarin therapy. Using a 5-year Markov model, we evaluated the health and economic outcomes associated with each of three different anticoagulation management approaches...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1018704318655

    authors: Lafata JE,Martin SA,Kaatz S,Ward RE

    更新日期:2000-06-01 00:00:00

  • Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.

    abstract::To analyze the efficacy and safety of activated prothrombin complex concentrates (aPCC) and four-factor prothrombin complex concentrates (4F-PCC) to prevent hematoma expansion in patients taking apixaban or rivaroxaban with intracranial hemorrhage (ICH). In this multicenter, retrospective study, sixty-seven ICH patien...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02154-z

    authors: Castillo R,Chan A,Atallah S,Derry K,Baje M,Zimmermann LL,Martin R,Groysman L,Stern-Nezer S,Minokadeh A,Nova A,Huang W,Cang W,Schomer K

    更新日期:2021-01-01 00:00:00

  • The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.

    abstract::The REG2 Anticoagulation System consists of pegnivacogin, a subcutaneously administered aptamer factor IXa inhibitor, and its intravenous active control agent, anivamersen. Its effect on thrombin generation is unknown. A prospectively designed thrombin generation study was conducted within the phase 1 ascending dose s...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-014-1081-6

    authors: Vavalle JP,Rusconi CP,Zelenkofske S,Wargin WA,Ortel TL,Alexander JH,Povsic TJ,Becker RC

    更新日期:2014-10-01 00:00:00

  • The impact of proton therapy on cardiotoxicity following radiation treatment.

    abstract::Cardiac disease following radiation therapy represents a major consideration in the treatment of a variety of malignancies. Damage to the heart can manifest in a variety of pathologies including ischemic cardiac disease, cardiomyopathy, valvular dysfunction, arrhythmias, and pericarditis. This damage has been shown to...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-020-02303-4

    authors: Frankart AJ,Nagarajan R,Pater L

    更新日期:2020-10-08 00:00:00

  • Comparison of clinical performance of four gastrointestinal bleeding risk scores in Chinese patients with atrial fibrillation receiving oral anticoagulants.

    abstract::Gastrointestinal bleeding is the most common bleeding complication during anticoagulant therapy. A reliable bleeding risk score can help the clinician assess risk of bleeding in individual patients and select the anticoagulant regimen. This study retrospectively analyzed the data of patients with atrial fibrillation w...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02152-1

    authors: Lv MN,Zheng XC,Zhang HQ,Xu FD,Wu TT,Chen WJ,Xia XT,Fu JL,Jiang SJ,Zhang JH

    更新日期:2021-01-01 00:00:00

  • COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis.

    abstract::Patients with COVID-19 are known to be at risk of developing both venous, arterial and microvascular thrombosis, due to an excessive immuno-thrombogenic response to the SARS-CoV-2 infection. Overlapping syndromes of COVID-19 associated coagulopathy with consumptive coagulopathy and microangiopathy can be seen in criti...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02318-x

    authors: Fan BE,Ng J,Chan SSW,Christopher D,Tso ACY,Ling LM,Young BE,Wong LJL,Sum CLL,Tan HT,Ang MK,Lim GH,Ong KH,Kuperan P,Chia YW

    更新日期:2020-10-24 00:00:00

  • Duration of anticoagulation for venous thromboembolism.

    abstract::The duration of oral anticoagulant therapy for venous thromboembolism (VTE) depends on the risk of recurrence if treatment is stopped and the risk of bleeding if treatment is continued. If the risk of recurrence is low (e.g., thrombosis provoked by a major reversible risk factor such as surgery), 3 months of treatment...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1023/a:1012790511790

    authors: Kearon C

    更新日期:2001-09-01 00:00:00

  • Newer anticoagulants in 2009.

    abstract::Several newer anticoagulants are under clinical development. Recently two of them, Dabigatran etexilate/Pradaxa. and Rivaroxaban/Xarelto obtained marketing authorization in Europe and Canada for the prevention of thromboembolic events following major orthopedic surgery such as total hip and knee replacement. The resul...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-009-0392-5

    authors: Samama MM,Gerotziafas GT

    更新日期:2010-01-01 00:00:00

  • Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients.

    abstract::Although clinical evidence supports a plausible association between thyroid disorders and venous thrombosis, reliable evidence is so far lacking on the potential biological mechanisms and neither temporary nor permanent thromboembolic risk factors were constantly identified. We performed a 2-years retrospective analys...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-008-0269-z

    authors: Lippi G,Franchini M,Targher G,Montagnana M,Salvagno GL,Guidi GC,Favaloro EJ

    更新日期:2009-10-01 00:00:00

  • Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials.

    abstract::This article focuses on lessons learned from clinical trials of antiplatelet therapies-in particular, that the degree of inhibition of ex vivo platelet aggregation does not necessarily directly translate into clinical efficacy. As an example, the case of the oral platelet glycoprotein IIb/IIIa inhibitors is presented,...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0160-3

    authors: Steinhubl SR,Schneider DJ,Berger PB,Becker RC

    更新日期:2008-08-01 00:00:00

  • Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy : Piazza: outcomes of high-bleeding risk AF patients.

    abstract::A perceived increased risk of bleeding is one of the most frequent reasons for withholding anticoagulation for stroke prevention in atrial fibrillation (AF). We previously conducted a randomized controlled trial of alert-based computerized decision support to increase prescription of anticoagulation in hospitalized pa...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02296-0

    authors: Piazza G,Hurwitz S,Carroll B,Goldhaber SZ

    更新日期:2020-09-30 00:00:00

  • Prevalence of common hereditary risk factors for thrombophilia in Somalia and identification of a novel Gln544Arg mutation in coagulation factor V.

    abstract::Thrombophilia, commonly manifested as venous thromboembolism (VTE), is a worldwide concern but little is known on its genetic epidemiology in many parts of the globe particularly in the developing countries. Here we employed TaqMan genotyping and pyrosequencing to evaluate the prevalence of known common nucleotide pol...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-017-1543-8

    authors: Abdi AA,Osman A

    更新日期:2017-11-01 00:00:00

  • Bivalirudin for left ventricular assist device thrombosis.

    abstract::Pump thrombosis remains a serious complication of implantable ventricular assist device therapy and is associated with increased risk of morbidity and mortality. Optimal management strategies remain controversial and are guided largely by limited literature and expert opinion. Medical management of pump thrombosis, in...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-018-1725-z

    authors: Weeks P,Sieg A,Rajapreyar I,Nathan S,Jumean M,Patel M,Radovancevic R,Kar B,Gregoric I

    更新日期:2018-11-01 00:00:00